MCID: ESP025
MIFTS: 63

Esophagus Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Rare diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Esophagus Adenocarcinoma

MalaCards integrated aliases for Esophagus Adenocarcinoma:

Name: Esophagus Adenocarcinoma 11 14
Esophageal Adenocarcinoma 58 16 75
Adenocarcinoma of Esophagus 43 71
Oesophageal Adenocarcinoma 11 33
Adenocarcinoma of the Esophagus 58

Characteristics:


Prevelance:

Adenocarcinoma of the Esophagus: 1-9/100000 (Europe, Europe, Europe, Austria, Belgium, Czech Republic, Finland, France, Germany, Iceland, Ireland, Malta, Switzerland, Netherlands, United Kingdom, Norway, Spain) 1-9/1000000 (Worldwide, Bulgaria, Croatia, Estonia, Italy, Latvia, Lithuania, Poland, Portugal, Slovakia, Slovenia) 58

Age Of Onset:

Adenocarcinoma of the Esophagus: Adult,Elderly 58

Classifications:

Orphanet: 58  
Rare gastroenterological diseases


External Ids:

Disease Ontology 11 DOID:4914
MeSH 43 C562730
NCIt 49 C4025
SNOMED-CT 68 276803003
ICD10 via Orphanet 32 C15.2 C15.5
UMLS via Orphanet 72 C0279628
Orphanet 58 ORPHA99976
UMLS 71 C0279628

Summaries for Esophagus Adenocarcinoma

Orphanet: 58 Esophageal adenocarcinoma (EAC) is a sub-type of esophageal carcinoma (EC; see this term) affecting the glandular cells of the lower esophagus at the junction with the stomach.

MalaCards based summary: Esophagus Adenocarcinoma, also known as esophageal adenocarcinoma, is related to peptic esophagitis and adenocarcinoma. An important gene associated with Esophagus Adenocarcinoma is HNF1A-AS1 (HNF1A Antisense RNA 1), and among its related pathways/superpathways are Cell differentiation - expanded index and Head and neck squamous cell carcinoma. The drugs FOLFIRINOX and Pertuzumab have been mentioned in the context of this disorder. Affiliated tissues include lymph node, liver and bone marrow, and related phenotypes are gastroesophageal reflux and feeding difficulties in infancy

Disease Ontology: 11 An esophageal carcinoma that derives from epithelial cells of glandular origin.

Wikipedia: 75 Esophageal cancer is cancer arising from the esophagus—the food pipe that runs between the throat and... more...

Related Diseases for Esophagus Adenocarcinoma

Diseases related to Esophagus Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 644)
# Related Disease Score Top Affiliating Genes
1 peptic esophagitis 30.9 CDX2 ATP4A ATP12A
2 adenocarcinoma 30.7 TP53 HNF1A-AS1 ERBB2 EGFR CDX2
3 gastroesophageal junction adenocarcinoma 30.7 TP53 ERBB2 EGFR
4 appendix adenocarcinoma 30.6 TP53 CDX2
5 cardia cancer 30.5 TP53 ERBB2 ATP4A ATP12A
6 atrophic gastritis 30.5 MIR196A1 CDX2 ATP4A ATP12A
7 mucinous adenocarcinoma 30.5 TP53 ERBB2 EGFR CDX2
8 pylorospasm 30.5 ATP4A ATP12A
9 barrett's adenocarcinoma 30.4 TP53 ERBB2 CDX2 ATP4A ATP12A
10 bile reflux 30.4 CDX2 ATP4A ATP12A
11 gastritis 30.4 TP53 MIR196A1 CDX2 ATP4A
12 alcohol use disorder 30.3 MIR199A1 MIR196A1 ATP12A
13 squamous cell carcinoma 30.2 TP53 MIR199A1 HNF1A-AS1 ERBB2 EGFR
14 achalasia 30.2 TP53 ATP4A ATP12A
15 barrett esophagus 30.2 TP53 TFF3 MIR196A1 ERBB2 CDX2 ATP4A
16 gastroesophageal adenocarcinoma 30.1 TP53 ERBB2 EGFR
17 signet ring cell adenocarcinoma 30.1 TP53 ERBB2 CDX2
18 exanthem 30.1 ERBB2 EGFR ATP12A
19 adenocarcinoma in situ 30.1 TP53 EGFR CDX2
20 small cell cancer of the lung 30.1 TP53 MIR21 EGFR
21 intestinal obstruction 30.1 CDX2 ATP4A ATP12A
22 apocrine adenocarcinoma 30.1 TP53 ERBB2 EGFR
23 tongue carcinoma 30.1 TP53 MIR21 MIR143 EGFR
24 glioma susceptibility 1 30.0 TP53 MIR21 ERBB2
25 skin carcinoma 30.0 TP53 MIR21 MIR199A1 ERBB2 EGFR
26 papillary adenocarcinoma 30.0 TP53 MIR21 ERBB2 CDX2
27 diffuse large b-cell lymphoma 30.0 MIR21 MIR199A1 MIR196A1 MIR145 MIR143
28 large cell carcinoma 29.9 TP53 MIR145 ERBB2 EGFR
29 kidney cancer 29.9 TP53 MIR21 MIR199A1 MIR193A MIR145 EGFR
30 intrahepatic cholangiocarcinoma 29.9 TP53 MIR199A1 ERBB2 EGFR
31 neurofibroma 29.9 TP53 ERBB2 EGFR
32 rectal benign neoplasm 29.9 TP53 MIR145 MIR143 LEPROTL1 EGFR CDX2
33 cholangiocarcinoma 29.9 TP53 MIR21 ERBB2 EGFR CDX2 AFAP1-AS1
34 lynch syndrome 29.9 TP53 ERBB2 EGFR CDX2
35 rectum cancer 29.9 TP53 MIR215 MIR21 MIR193A MIR145 MIR143
36 colorectal adenocarcinoma 29.8 TP53 MIR193A MIR145 MIR143 ERBB2 EGFR
37 gastroesophageal reflux 29.8 TP53 EGFR CDX2 ATP4A ATP12A
38 hematologic cancer 29.8 MIR21 MIR199A1 MIR196A1 MIR193A MIR145 MIR143
39 microinvasive gastric cancer 29.8 TP53 MIR199A1 MIR196A1 ERBB2 CDX2 ATP4A
40 bladder cancer 29.7 TP53 MIR21 MIR199A1 MIR145 MIR143 HNF1A-AS1
41 esophageal disease 29.7 TP53 MIR330 MIR21 MIR199A1 MIR196A1 MIR193A
42 lymphatic system disease 29.7 TP53 MIR21 MIR199A1 MIR196A1 MIR193A MIR145
43 oropharynx cancer 29.7 TP53 MIR21 MIR199A1 MIR196A1 ERBB2 EGFR
44 lung squamous cell carcinoma 29.7 TP53 MIR330 MIR196A1 MIR193A MIR145 EGFR
45 gastrointestinal system disease 29.6 MIR330 MIR215 MIR21 MIR199A1 MIR196A1 MIR193A
46 body mass index quantitative trait locus 11 29.6 TP53 MIR21 MIR199A1 MIR196A1 MIR193A MIR143
47 leukemia, chronic myeloid 29.6 TP53 MIR199A1 MIR196A1 MIR193A ERBB2 EGFR
48 gastrointestinal system cancer 29.6 MIR330 MIR215 MIR21 MIR199A1 MIR196A1 MIR193A
49 thoracic cancer 29.5 MIR330 MIR21 MIR199A1 MIR196A1 MIR193A MIR145
50 gastric cancer 29.4 TP53 TFF3 MIR215 MIR21 MIR199A1 MIR196A1

Graphical network of the top 20 diseases related to Esophagus Adenocarcinoma:



Diseases related to Esophagus Adenocarcinoma

Symptoms & Phenotypes for Esophagus Adenocarcinoma

Human phenotypes related to Esophagus Adenocarcinoma:

58 30 (show all 10)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 gastroesophageal reflux 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0002020
2 feeding difficulties in infancy 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0008872
3 obesity 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001513
4 clinodactyly of the 5th toe 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0001864
5 barrett esophagus 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0100580
6 esophageal carcinoma 58 30 Hallmark (90%) Very frequent (99-80%)
HP:0011459
7 nausea and vomiting 58 30 Frequent (33%) Frequent (79-30%)
HP:0002017
8 cough 58 30 Frequent (33%) Frequent (79-30%)
HP:0012735
9 chest pain 58 30 Frequent (33%) Frequent (79-30%)
HP:0100749
10 lymphadenopathy 58 30 Occasional (7.5%) Occasional (29-5%)
HP:0002716

Drugs & Therapeutics for Esophagus Adenocarcinoma

Drugs for Esophagus Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 149)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 FOLFIRINOX Phase 4
2
Pertuzumab Approved Phase 3 380610-27-5
3
Levoleucovorin Approved, Experimental, Investigational Phase 3 68538-85-2, 58-05-9, 73951-54-9 149436 6006
4
Capecitabine Approved, Investigational Phase 3 154361-50-9 60953
5
Ipilimumab Approved Phase 3 477202-00-9
6
Ramucirumab Approved, Investigational Phase 2, Phase 3 947687-13-0
7
Tucatinib Approved, Investigational Phase 2, Phase 3 937263-43-9 51039094
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
9 Hematoporphyrins Phase 3
10 Pharmaceutical Solutions Phase 3
11 Antibodies, Bispecific Phase 3
12 Folate Phase 3
13 Vitamin B9 Phase 3
14 Vitamins Phase 3
15 Trace Elements Phase 3
16 Vitamin B Complex Phase 3
17 Antidotes Phase 3
18 Micronutrients Phase 3
19 Protective Agents Phase 3
20 Trastuzumab biosimilar HLX02 Phase 3
21
Trioxsalen Approved Phase 2 3902-71-4 5585
22
Bevacizumab Approved, Investigational Phase 2 216974-75-3 135329020
23
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
24
Erlotinib Approved, Investigational Phase 2 183319-69-9, 183321-74-6 176870
25
Everolimus Approved Phase 1, Phase 2 159351-69-6 70789204 6442177
26
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
27
Sunitinib Approved, Investigational Phase 2 557795-19-4 5329102
28
Proflavine Approved Phase 2 92-62-6 7099
29
Propranolol Approved, Investigational Phase 2 318-98-9, 525-66-6 62882 4946
30
Rucaparib Approved, Investigational Phase 1, Phase 2 283173-50-2 9931954
31
Rosiglitazone Approved, Investigational Phase 2 122320-73-4, 155141-29-0 77999
32
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
33
Lenvatinib Approved, Investigational Phase 2 417716-92-8 9823820
34
Fulvestrant Approved, Investigational Phase 1, Phase 2 129453-61-8 17756771 104741
35
Sirolimus Approved, Investigational Phase 2 53123-88-9 5284616 6436030
36
Adenosine Approved, Investigational Phase 2 58-61-7 60961
37
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
38
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
39
Trifluridine Approved, Investigational Phase 2 70-00-8 6256
40
Durvalumab Approved, Investigational Phase 2 1428935-60-7
41
Tremelimumab Approved, Investigational Phase 2 745013-59-6
42
Avelumab Approved, Investigational Phase 2 1537032-82-8
43
Itraconazole Approved, Investigational Phase 2 84625-61-6 55283
44
Miconazole Approved, Investigational, Vet_approved Phase 2 22916-47-8 4189
45
Clotrimazole Approved, Vet_approved Phase 2 23593-75-1 2812
46
Carboplatin Approved Phase 2 41575-94-4 10339178 38904
47
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
48
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
49
Irinotecan Approved, Investigational Phase 2 97682-44-5, 100286-90-6 60838
50
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 5702198 441203

Interventional clinical trials:

(show top 50) (show all 198)
# Name Status NCT ID Phase Drugs
1 PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma Recruiting NCT02366819 Phase 4 Oxaliplatin;Leucovorin Calcium;Irinotecan Hydrochloride;Fluorouracil
2 Two-arm Phase III Trial Comparing Different Time of Endoscopic Photodynamic Therapy on Esophageal and/or Gastric Cardiac Cancer Unknown status NCT02628665 Phase 3 photosensitizer(photofrin)
3 Confocal Laser Endomicroscopy for Improved Diagnosis of Barrett's Esophagus and Associated Neoplasia Completed NCT00487695 Phase 3
4 Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer Recruiting NCT03801876 Phase 3 Carboplatin;Paclitaxel;FOLFOX regimen;CAPOX regimen;Docetaxel;5FU
5 A Phase III Study of Consolidative Radiotherapy in Patients With Oligometastatic HER2 Negative Esophageal and Gastric Adenocarcinoma (EGA) Recruiting NCT04248452 Phase 3 Capecitabine;Fluorouracil;Leucovorin;Leucovorin Calcium;Oxaliplatin
6 A Phase II/III Study of Peri-Operative Nivolumab and Ipilimumab in Patients With Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma Recruiting NCT03604991 Phase 2, Phase 3 Carboplatin;Paclitaxel
7 A Randomized, Open-Label, Multicenter Phase 3 Trial of Domvanalimab, Zimberelimab, and Chemotherapy Versus Nivolumab and Chemotherapy in Participants With Previously Untreated Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinoma Recruiting NCT05568095 Phase 3 Zimberelimab;Domvanalimab;Nivolumab;Oxaliplatin;Leucovorin;Fluorouracil;Capecitabine
8 A Randomized, Double-blind, Placebo-controlled Phase 3 Trial of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Receiving Concurrent Definitive Chemoradiotherapy (KEYNOTE 975) Recruiting NCT04210115 Phase 3 placebo;cisplatin;5-FU;leucovorin;levoleucovorin;oxaliplatin
9 The Efficacy of the Addition of TRAstuzumab and Pertuzumab to Neoadjuvant Chemoradiation: a Randomized Multi-center Study in Resectable HER2 Overexpressing Adenocarcinoma of the Esophagus or Gastroesophageal Junction. The TRAP-2 Study Recruiting NCT05188313 Phase 3 Trastuzumab;Pertuzumab;Paclitaxel;Carboplatin
10 A Randomized, Multicenter, Phase 3 Study of Zanidatamab in Combination With Chemotherapy With or Without Tislelizumab in Subjects With HER2-positive Unresectable Locally Advanced or Metastatic Gastroesophageal Adenocarcinoma (GEA) Recruiting NCT05152147 Phase 3 Zanidatamab;Tislelizumab;Trastuzumab;Capecitabine;Oxaliplatin;Cisplatin;5-Fluorouracil
11 A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma Active, not recruiting NCT01196390 Phase 3 Carboplatin;Paclitaxel
12 Perioperative Chemotherapy (FLOT Protocol) Compared To Neoadjuvant Chemoradiation (CROSS Protocol) in Patients With Adenocarcinoma of the Esophagus Active, not recruiting NCT02509286 Phase 3 5-Fluorouracil;Leucovorin;Oxaliplatin;Docetaxel;Carboplatin;Paclitaxel
13 A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC) Active, not recruiting NCT04499924 Phase 2, Phase 3 tucatinib;trastuzumab;ramucirumab;paclitaxel
14 A Randomized, Multicenter, Open-Label, Phase 3 Study of Nivolumab Plus Ipilimumab or Nivolumab in Combination With Oxaliplatin Plus Fluoropyrimidine Versus Oxaliplatin Plus Fluoropyrimidine in Subjects With Previously Untreated Advanced or Metastatic Gastric or Gastroesophageal Junction Cancer Active, not recruiting NCT02872116 Phase 3 Nivolumab;Ipilimumab;Oxaliplatin;Capecitabine;Leucovorin;Fluorouracil
15 Nutritional Supplementation for Esophageal Cancer Patients Undergoing Trimodality Therapy Not yet recruiting NCT04029857 Phase 3
16 A Phase Ib/II Study of MBP-426 in Patients With Second Line Gastric, Gastro Esophageal, or Esophageal Adenocarcinoma Unknown status NCT00964080 Phase 1, Phase 2 MBP-426/Leucovorin/5-FU
17 A Phase 1B/2 Study of Taladegib in Combination With Weekly Paclitaxel, Carboplatin, and Radiation in Localized Adenocarcinoma of the Esophagus or Gastroesophageal Junction Completed NCT02530437 Phase 1, Phase 2 Carboplatin;Paclitaxel;Taladegib
18 Pralatrexate in Combination With Oxaliplatin in Advanced Esophago-gastric Cancer: A Phase II Trial With Predictive Molecular Correlates Completed NCT01178944 Phase 2 Oxaliplatin;Pralatrexate
19 Phase II Study of Irinotecan and Panitumumab as Second-Line Therapy for Patients With Advanced Esophageal Adenocarcinoma Completed NCT00836277 Phase 2 Panitumumab;Irinotecan
20 A Randomized, Double Blind, Multi-Center, Phase 2 Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination With AMG 386 or Placebo in Subjects With Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma Completed NCT00583674 Phase 2 AMG 386 placebo;AMG 386 10mg/kg;AMG 386 3mg/kg;Cisplatin;Capecitabine
21 Phase II Trial of Irinotecan, Cisplatin, Bevacizumab and Concurrent Radiotherapy in Locally Advanced Esophageal Adenocarcinoma Completed NCT00354679 Phase 2 cisplatin;irinotecan hydrochloride
22 PANGEA: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma Completed NCT02213289 Phase 2 Trastuzumab;ABT-806;Bemarituzumab;Ramucirumab;Nivolumab;Standard cytotherapy
23 Pilot Study of Perioperative Docetaxel, Oxaliplatin, and 5-Fluorouracil (FLOT) in Patients With Gastric or Gastroesophageal Junction Adenocarcinoma Completed NCT01932580 Phase 2 FLOT (5-fluorouracil, oxaliplatin, docetaxel)
24 Randomized Controlled Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer Completed NCT02128243 Phase 2 S-1 de-escalation;Chemotherapy by Investigator's choice
25 A Randomized Discontinuation Study of Brivanib Alaninate (BMS-582664) Versus Placebo in Subjects With Advanced Tumors Completed NCT00633789 Phase 2 brivanib;Placebo
26 Modular Phase 2 Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies. Completed NCT03365791 Phase 2
27 Endoscopic Therapy of Early Cancer in Barretts Esophagus Completed NCT00217087 Phase 2
28 An Open-Labeled, Multicenter Phase II Study of Cabazitaxel in Refractory Metastatic Gastric or Gastroesophageal Adenocarcinoma Completed NCT01757171 Phase 2 Cabazitaxel
29 A Phase II Study of Doxorubicin, Cisplatin, and 5-Fluorouracil in Patients With Advanced Adenocarcinoma of the Stomach or Esophagus Completed NCT00165191 Phase 2 Doxorubicin;Cisplatin;5-fluorouracil
30 A Randomized Phase II Multicenter, Open-Label Study Evaluating the Efficacy and Safety of IMAB362 in Combination With the EOX (Epirubicin, Oxaliplatin, Capecitabine) Regimen as First-Line Treatment of Patients With CLDN18.2-Positive Advanced Adenocarcinomas of the Stomach, the Esophagus or the Gastroesophageal Junction Completed NCT01630083 Phase 2 epirubicin;oxaliplatin;capecitabine;zolbetuximab
31 Phase II Trial of Cetuximab, Irinotecan, Cisplatin (CPC), Concurrent Radiation Therapy, and Surgery for Resectable Esophageal Cancer Completed NCT00165490 Phase 2 Cetuximab;Cisplatin;Irinotecan
32 Pre-operative Epirubicin, Capecitabine (Xeloda) and Cisplatin in Patients With Newly Diagnosed Localised Oesophageal Adenocarcinoma Completed NCT00220103 Phase 2 epirubicin, capecitabine, cisplatin
33 A Phase II Study of Erlotinib and Modified FOLFOX-6 (5-Fluorouracil, Leucovorin and Oxaliplatin) in Previously Untreated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Gastric Cardia Completed NCT00591123 Phase 2 FOLFOX;5-FU;Erlotinib
34 Palliative Short-course Hypofractionated Radiotherapy Followed by Chemotherapy in Adenocarcinoma of the Esophagus or Esophagogastric Junction Trial - a Phase II Clinical Trial Protocol. Completed NCT02241499 Phase 2 Oxaliplatin and fluorouracil.
35 A Phase II Study Of Triapine In Combination With Cisplatin Esophageal Carcinoma Completed NCT00077545 Phase 2 triapine;cisplatin
36 Phase II Study of Pralatrexate and Docetaxel in Patients With Advanced Esophageal and Gastroesophageal Carcinoma Who Have Failed Prior Platinum-based Therapy. Completed NCT01129206 Phase 2 pralatrexate;docetaxel
37 Phase II Study Of OSI-774 In Advanced Esophageal Cancer Completed NCT00045526 Phase 2 erlotinib hydrochloride
38 Pilot Trial of CRLX101 in the Treatment of Patients With Advanced Gastric, Gastroesophageal, or Esophageal Squamous or Adenocarcinoma Completed NCT01612546 Phase 2 cyclodextrin-based polymer-camptothecin CRLX101
39 Phase Ib Trial of mFOLFOX6 and Everolimus (NSC-733504) in Patients With Metastatic Gastroesophageal Adenocarcinoma Completed NCT01231399 Phase 1, Phase 2 fluorouracil;leucovorin calcium;oxaliplatin;everolimus
40 Phase II Trial of Pre-operative Bevacizumab and FOLFOX Chemotherapy in Locally Advanced Esophageal Cancer Completed NCT01212822 Phase 2 oxaliplatin;leucovorin calcium;fluorouracil
41 Adjuvant Treatment of Cancer of the Esophagus or Cardia Before Resection With Curative Intent. Comparative Study Between Chemotherapy and Radiochemotherapy Completed NCT01362127 Phase 2 Chemotherapy
42 A Phase II Study Of Preoperative Celecoxib/Paclitaxel/Carboplatin For Squamous Cell And Adenocarcinoma Of The Esophagus Completed NCT00066716 Phase 2 carboplatin;celecoxib;paclitaxel
43 Randomized Phase II Study of Preoperative Combined Modality Paclitaxel / Cisplatin / RT or Irinotecan / Cisplatin / RT Followed by Postoperative Chemotherapy With the Same Agents in Operable Adenocarcinoma of the Esophagus Completed NCT00033657 Phase 2 cisplatin;irinotecan hydrochloride;paclitaxel
44 A Phase II Study of the mTOR Inhibitor RAD001 in Previously Treated Patients With Unresectable or Metastatic Adenocarcinoma of the Esophagus and Stomach Completed NCT00985192 Phase 2 everolimus
45 A Phase II, Open-Label Study Evaluating Clinical Efficacy, Safety, Pharmacokinetic and Pharmacodynamic Effects of Lapatinib (GW572016) in Patients With Relapsed Adenocarcinoma of the Esophagus, Including Tumors of the Gastroesophageal Junction and Gastric Cardia Completed NCT00259987 Phase 2 Lapatinib (GW572016) oral tablets
46 Phase II Trial of Post-Operative Adjuvant Paclitaxel + Cisplatin in Patients With Adenocarcinoma of the Esophagus, Gastro-Esophageal Junction or Cardia Completed NCT00003237 Phase 2 cisplatin;paclitaxel
47 Randomized Phase II Trial of Extended Neoadjuvant Therapy for Locally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia Completed NCT00938470 Phase 2 capecitabine;docetaxel;fluorouracil;oxaliplatin
48 A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction Completed NCT00891878 Phase 2 capecitabine;sunitinib malate
49 A Phase II Trial of Induction Chemotherapy With Epirubicin, Oxaliplatin and Fluorouracil (EOF) Followed by Esophagogastrectomy and Post-operative Concurrent Chemoradiotherapy With Fluorouracil and Cisplatin, in Patients With Loco-regionally Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction and Gastric Cardia Completed NCT00601705 Phase 2 cisplatin;epirubicin hydrochloride;fluorouracil;oxaliplatin
50 A Phase II Study of Oxaliplatin and Capecitabine in Patients With Measurable Metastatic Adenocarcinoma of the Esophagus, Gastroesophageal Junction, and Gastric Cardia Completed NCT00040859 Phase 2 capecitabine;oxaliplatin

Search NIH Clinical Center for Esophagus Adenocarcinoma

Cochrane evidence based reviews: adenocarcinoma of esophagus

Genetic Tests for Esophagus Adenocarcinoma

Anatomical Context for Esophagus Adenocarcinoma

Organs/tissues related to Esophagus Adenocarcinoma:

MalaCards : Lymph Node, Liver, Bone Marrow, Skeletal Muscle, Lung, Breast, Endothelial

Publications for Esophagus Adenocarcinoma

Articles related to Esophagus Adenocarcinoma:

(show top 50) (show all 6524)
# Title Authors PMID Year
1
MicroRNA profiling of Barrett's oesophagus and oesophageal adenocarcinoma. 62 46
20301167 2010
2
Cervical esophageal adenocarcinoma of intestinal type in ectopic gastric mucosa. 62
35898822 2023
3
Incidence and Impact of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Adenocarcinoma of the Esophagus Treated with Curative Intent. 62
36264338 2023
4
Patient Knowledge, Risk Perception, and Barriers to Barrett's Esophagus Screening. 62
36219171 2022
5
AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review. 62
35788412 2022
6
Diverse contributions of the visceral fat area to the etiology of two distinct subtypes of esophago-gastric junctional adenocarcinoma. 62
35737566 2022
7
Perspectives on the pharmacological management of esophageal cancer: where are we now and where do we need to go? 62
36286544 2022
8
Next Generation Sequencing for Potential Regulated Genes and Micro-RNAs of Early Growth Response-1 in the Esophageal Squamous Cell Carcinoma. 62
36207572 2022
9
Detection of Barrett's neoplasia with a near-infrared fluorescent heterodimeric peptide. 62
35299273 2022
10
Long-term fear of cancer recurrence in patients treated endoscopically for early Barrett's neoplasia. 62
36461786 2022
11
Integrin beta1 (ITGB1) as a prognostic marker in esophageal adenocarcinoma. 62
36456612 2022
12
Change in Density Not Size of Esophageal Adenocarcinoma During Neoadjuvant Chemotherapy Is Associated with Improved Survival Outcomes. 62
36214951 2022
13
Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma. 62
36253523 2022
14
Risk of gastric and oesophageal adenocarcinoma following discontinuation of long-term proton-pump inhibitor therapy. 62
36258093 2022
15
Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy. 62
36445478 2022
16
Generation and multiomic profiling of a TP53/CDKN2A double-knockout gastroesophageal junction organoid model. 62
36449602 2022
17
Controversies in upper gastrointestinal oncology: neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy in oesophageal adenocarcinoma. 62
36356415 2022
18
RAD51 Is Implicated in DNA Damage, Chemoresistance and Immune Dysregulation in Solid Tumors. 62
36428789 2022
19
The Ephrin B2 Receptor Tyrosine Kinase Is a Regulator of Proto-oncogene MYC and Molecular Programs Central to Barrett's Neoplasia. 62
35870513 2022
20
Antitumor effects of lactate transport inhibition on esophageal adenocarcinoma cells. 62
36342616 2022
21
An International Cohort Study of Prognosis Associated With Pathologically Complete Response Following Neoadjuvant Chemotherapy Versus Chemoradiotherapy of Surgical Treated Esophageal Adenocarcinoma. 62
35861351 2022
22
Clinical Understaging, Treatment Response, and Survival Among Esophageal Adenocarcinoma Patients. 62
35797753 2022
23
Comment on: The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-Negative Esophageal Adenocarcinoma. 62
34793349 2022
24
[Oesogastric cancer - new therapeutic targets]. 62
36371284 2022
25
Safety and efficacy of liquid nitrogen spray cryotherapy in Barrett's neoplasia - a comprehensive review and meta-analysis. 62
36397870 2022
26
Global variations in diagnostic guidelines for Barrett's esophagus. 62
35475586 2022
27
Barrett's Esophagus and Esophageal Adenocarcinoma: A Histopathological Perspective. 62
36266029 2022
28
Development and External Validation of a Model to Predict Complex Treatment After Radiofrequency Ablation for Barrett's Esophagus With Early Neoplasia. 62
35292379 2022
29
A risk variant for Barrett's esophagus and esophageal adenocarcinoma at chr8p23.1 affects enhancer activity and implicates multiple gene targets. 62
35766871 2022
30
CROSS Versus FLOT Regimens in Esophageal and Esophagogastric Junction Adenocarcinoma: A Propensity-Matched Comparison. 62
35876385 2022
31
Prognostic and predictive biomarkers for response to neoadjuvant chemoradiation in esophageal adenocarcinoma. 62
36376989 2022
32
Proton Beam Therapy With Space-Making Surgery (Omental Plombage) for Oligorecurrent Liver Metastasis of Esophageal Adenocarcinoma. 62
36415474 2022
33
Evaluation of Clinical and Safety Outcomes of Neoadjuvant Immunotherapy Combined With Chemotherapy for Patients With Resectable Esophageal Cancer: A Systematic Review and Meta-analysis. 62
36322089 2022
34
Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer. 62
36334593 2022
35
Ongoing Controversies in Esophageal Cancer II: Gastrectomy versus Esophagectomy for Siewert Type II Esophageal Adenocarcinoma. 62
36266040 2022
36
Immune Checkpoint Blockade and Targeted Therapies in Esophageal Cancer. 62
36266034 2022
37
High spicy food intake may increase the risk of esophageal cancer: A meta-analysis and systematic review. 62
36215887 2022
38
Esophageal Cancer Genetics and Clinical Translation. 62
36266030 2022
39
Global and national trends in the age-specific sex ratio of esophageal cancer and gastric cancer by subtype. 62
35678331 2022
40
Laparoscopic total fundoplication is superior to medical treatment for reducing the cancer risk in Barrett's esophagus: a long-term analysis. 62
35641160 2022
41
Effect of hiatus hernia on reflux patterns and mucosal integrity in patients with non-erosive reflux disease. 62
35593218 2022
42
Low Prevalence of Endoscopic Screening for Barrett's Esophagus in a Screening-Eligible Primary Care Population. 62
35971219 2022
43
A blood-based circulating microbial metagenomic panel for early diagnosis and prognosis of oesophageal adenocarcinoma. 62
36097175 2022
44
Gastroesophageal Reflux Disease Is Not a Great Screening Criterion: Time to Move on to Other Strategies for Controlling the Burden of Esophageal Adenocarcinoma. 62
36327434 2022
45
Progressive dysbiosis of human orodigestive microbiota along the sequence of gastroesophageal reflux, Barrett's esophagus and esophageal adenocarcinoma. 62
35751398 2022
46
Sleeve-Dor Fundoplication - An Innovative Surgical Technique to Avoid the Epidemic Long Term de Novo Gastroesophageal Reflux and Barrett´s Esophagus After Sleeve Gastrectomy for Obesity. 62
36413570 2022
47
Barrett Esophagus: Rapid Evidence Review. 62
36260894 2022
48
Augmented CPT1A Expression Is Associated with Proliferation and Colony Formation during Barrett's Tumorigenesis. 62
36233047 2022
49
Columnar Metaplasia of the Esophagus Presenting as Iron Deficiency Anemia in Children with Neurologic Impairment or Congenital Esophageal Atresia. 62
36225096 2022
50
International trends in esophageal cancer incidence rates by histological subtype (1990-2012) and prediction of the rates to 2030. 62
35689719 2022

Variations for Esophagus Adenocarcinoma

Cosmic variations for Esophagus Adenocarcinoma:

8 (show top 50) (show all 11464)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM94780361 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 10
2 COSM131486960 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1159G>A p.A387T 18:25226759-25226759 10
3 COSM140706619 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.499G>A p.A167T 18:25226759-25226759 10
4 COSM94777296 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 10
5 COSM131495211 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 10
6 COSM140704933 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.1625G>A p.R542H 18:25225633-25225633 10
7 COSM94795709 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 10
8 COSM94788727 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.443G>A p.C148Y 18:25227475-25227475 10
9 COSM140712668 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.-218G>A p.? 18:25227475-25227475 10
10 COSM131483683 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2285G>A p.R762H 18:25225633-25225633 10
11 COSM131502188 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.3434T>G p.V1145G 18:25224484-25224484 10
12 COSM140717636 ZNF521 stomach,NS,carcinoma,adenocarcinoma c.2774T>G p.V925G 18:25224484-25224484 10
13 COSM89892679 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1136G>A p.R379Q 12:6669044-6669044 10
14 COSM99686061 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1319G>A p.R440Q 12:6669044-6669044 10
15 COSM96892872 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.1319G>A p.R440Q 12:6669044-6669044 10
16 COSM92495186 ZNF384 stomach,NS,carcinoma,adenocarcinoma c.971G>A p.R324Q 12:6669044-6669044 10
17 COSM90523509 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2512G>A p.A838T 20:33791485-33791485 10
18 COSM98293254 ZNF341 stomach,NS,carcinoma,adenocarcinoma c.2533G>A p.A845T 20:33791485-33791485 10
19 COSM84509305 ZNF276 stomach,NS,carcinoma,adenocarcinoma c.*677T>G p.? 16:89738923-89738923 10
20 COSM102042239 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5456G>T p.R1819L 16:72794484-72794484 10
21 COSM149288723 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 10
22 COSM149261321 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 10
23 COSM102020152 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-7323C>T p.? 16:72958288-72958288 10
24 COSM87271088 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1858C>T p.H620Y 16:72958288-72958288 10
25 COSM87290698 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 10
26 COSM87291716 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 10
27 COSM149332052 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 10
28 COSM87280547 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1081G>A p.G361R 16:72959065-72959065 10
29 COSM102040971 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-8386C>A p.? 16:72959351-72959351 10
30 COSM87291652 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 10
31 COSM87296752 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.5929G>C p.G1977R 16:72796753-72796753 10
32 COSM149318848 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.4553G>T p.G1518V 16:72798129-72798129 10
33 COSM149318790 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.8198G>T p.R2733L 16:72794484-72794484 10
34 COSM102042308 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.1811G>T p.G604V 16:72798129-72798129 10
35 COSM149315912 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.795C>A p.D265E 16:72959351-72959351 10
36 COSM102030210 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.-23-8100G>A p.? 16:72959065-72959065 10
37 COSM102048038 ZFHX3 stomach,NS,carcinoma,adenocarcinoma c.3187G>C p.G1063R 16:72796753-72796753 10
38 COSM89893344 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 10
39 COSM136835352 YES1 stomach,NS,carcinoma,adenocarcinoma c.365G>A p.R122K 18:751726-751726 10
40 COSM152021882 YES1 stomach,NS,carcinoma,adenocarcinoma c.350G>A p.R117K 18:751726-751726 10
41 COSM143039512 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 10
42 COSM145026456 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 10
43 COSM85235472 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 10
44 COSM128450026 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 10
45 COSM126971185 YAP1 stomach,NS,carcinoma,adenocarcinoma c.-179C>G p.? 11:102114178-102114178 10
46 COSM133271379 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 10
47 COSM127996054 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 10
48 COSM90945716 YAP1 stomach,NS,carcinoma,adenocarcinoma c.356C>G p.T119S 11:102114178-102114178 10
49 COSM97252932 XRCC2 stomach,NS,carcinoma,adenocarcinoma c.140A>G p.H47R 7:152649345-152649345 10
50 COSM101975785 XPO1 stomach,NS,carcinoma,adenocarcinoma c.479G>A p.S160N 2:61499824-61499824 10

Copy number variations for Esophagus Adenocarcinoma from CNVD:

6 (show top 50) (show all 85)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 18052 1 143700001 144900000 Amplification BCL9 Esophageal adenocarcinoma
2 19685 1 151000001 155000000 Amplification SKI Esophageal adenocarcinoma
3 29301 1 2300000 5400000 Copy number Esophageal adenocarcinoma
4 37058 1 84900000 107200000 Loss F3 Esophageal adenocarcinoma
5 47055 10 89500000 92900000 Copy number Esophageal adenocarcinoma
6 49101 11 102900000 110400000 Copy number Esophageal adenocarcinoma
7 53078 11 2400000 5900000 Copy number CDKN1C Esophageal adenocarcinoma
8 57455 11 63400000 77100000 Gain CCND1 Esophageal adenocarcinoma
9 57457 11 63400000 77100000 Gain CTTN Esophageal adenocarcinoma
10 57458 11 63400000 77100000 Gain FGF3 Esophageal adenocarcinoma
11 64928 12 133416937 133464204 Copy number CHFR Esophageal adenocarcinoma
12 76216 13 28900000 32200000 Gain BRCA2 Esophageal adenocarcinoma
13 80630 13 95000000 115169878 Gain ABCC4 Esophageal adenocarcinoma
14 80631 13 95000000 115169878 Gain ING1 Esophageal adenocarcinoma
15 92864 15 44800000 63700000 Loss B2M Esophageal adenocarcinoma
16 95624 15 78300000 102531392 Loss IGF1R Esophageal adenocarcinoma
17 105374 16 7900000 10500000 Copy number Esophageal adenocarcinoma
18 106764 17 1 20774742 Copy number MYBBP1A Esophageal adenocarcinoma
19 106765 17 1 20774742 Copy number TP53 Esophageal adenocarcinoma
20 109778 17 2912016 3092354 Gain and loss Esophageal adenocarcinoma
21 110805 17 34303536 34308523 Gain CCL3 Esophageal adenocarcinoma
22 112093 17 37856253 37884915 Gain ERBB2 Esophageal adenocarcinoma
23 112536 17 400000 1400000 Copy number Esophageal adenocarcinoma
24 118020 17 7512444 7519279 Deletion TP53 Esophageal adenocarcinoma
25 119909 18 18180001 18280000 Amplification CTAGE1 Esophageal adenocarcinoma
26 121327 18 42300001 49000000 Copy number Esophageal adenocarcinoma
27 121739 18 46700000 46950000 Copy number ELAC1 Esophageal adenocarcinoma
28 121740 18 46700000 46950000 Copy number ME2 Esophageal adenocarcinoma
29 121741 18 46700000 46950000 Copy number SMAD4 Esophageal adenocarcinoma
30 121934 18 49866541 51062273 Loss DCC Esophageal adenocarcinoma
31 122288 18 54600001 58000000 Copy number MC4R Esophageal adenocarcinoma
32 122514 18 57567191 57571538 Loss PMAIP1 Esophageal adenocarcinoma
33 122776 18 60790578 60986613 Loss BCL2 Esophageal adenocarcinoma
34 123455 18 72900000 73900000 Copy number GALR1 Esophageal adenocarcinoma
35 123456 18 72900000 73900000 Copy number MBP Esophageal adenocarcinoma
36 134361 2 10000000 85000000 Copy number MSH2 Esophageal adenocarcinoma
37 134362 2 10000000 85000000 Copy number MYCN Esophageal adenocarcinoma
38 142764 2 230000001 238400000 Copy number Esophageal adenocarcinoma
39 150784 20 14500000 15536000 Copy number Esophageal adenocarcinoma
40 153497 20 37600000 49800000 Gain NCOA3 Esophageal adenocarcinoma
41 153498 20 37600000 49800000 Gain PTPN1 Esophageal adenocarcinoma
42 154843 20 49100001 52300000 Amplification ZNF217 Esophageal adenocarcinoma
43 157694 21 21500001 25000000 Copy number Esophageal adenocarcinoma
44 157695 21 21500001 25000000 Copy number NCAM2 Esophageal adenocarcinoma
45 162985 22 23500000 25900000 Loss MIF Esophageal adenocarcinoma
46 190407 4 88000000 98800000 Loss ABCG2 Esophageal adenocarcinoma
47 190850 4 91513360 92060333 Copy number Esophageal adenocarcinoma
48 193495 5 130600000 144500000 Loss IL13 Esophageal adenocarcinoma
49 200116 5 50107903 180611420 Gain and loss APC Esophageal adenocarcinoma
50 200117 5 50107903 180611420 Gain and loss CCNB1 Esophageal adenocarcinoma

Expression for Esophagus Adenocarcinoma

Search GEO for disease gene expression data for Esophagus Adenocarcinoma.

Pathways for Esophagus Adenocarcinoma

Pathways related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
11.4 MIR199A1 MIR145 MIR143
2 11.3 TP53 ERBB2 EGFR
3 11.12 MIR21 MIR199A1 MIR145
4 10.85 TP53 MIR330 MIR21 MIR145 MIR143
5 10.73 TP53 ERBB2 EGFR

GO Terms for Esophagus Adenocarcinoma

Cellular components related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RISC complex GO:0016442 9.58 MIR505 MIR345 MIR330 MIR215 MIR21 MIR199A1

Biological processes related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein kinase B signaling GO:0051897 9.88 MIR21 MIR199A1 MIR143 EGFR
2 regulation of ERK1 and ERK2 cascade GO:0070372 9.83 MIR145 ERBB2 EGFR
3 negative regulation of cell migration involved in sprouting angiogenesis GO:0090051 9.63 MIR199A1 MIR196A1 MIR193A
4 miRNA-mediated gene silencing GO:0035195 9.6 MIR505 MIR345 MIR330 MIR215 MIR21 MIR199A1
5 negative regulation of cardiac muscle cell apoptotic process GO:0010667 9.58 MIR21 MIR199A1 MIR145
6 positive regulation of miRNA maturation GO:1903800 9.51 TP53 EGFR
7 aorta smooth muscle tissue morphogenesis GO:0060414 9.49 MIR145 MIR143
8 regulation of phenotypic switching GO:1900239 9.37 MIR145 MIR143
9 negative regulation of angiogenesis GO:0016525 9.35 MIR505 MIR21 MIR193A MIR145 MIR143
10 negative regulation of interleukin-21 production GO:0032705 9.32 MIR215 MIR21
11 positive regulation of cellular response to hypoxia GO:1900039 9.26 MIR21 MIR145
12 establishment or maintenance of cell type involved in phenotypic switching GO:0044663 9.16 MIR143 MIR145

Molecular functions related to Esophagus Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 P-type sodium:potassium-exchanging transporter activity GO:0005391 9.62 ATP4A ATP12A
2 mRNA 3'-UTR binding GO:0003730 9.5 TP53 MIR21 MIR199A1 MIR193A MIR145 MIR143
3 P-type potassium:proton transporter activity GO:0008900 9.46 ATP4A ATP12A
4 mRNA base-pairing translational repressor activity GO:1903231 9.32 MIR505 MIR345 MIR330 MIR215 MIR21 MIR199A1
5 P-type potassium transmembrane transporter activity GO:0008556 9.26 ATP4A ATP12A

Sources for Esophagus Adenocarcinoma

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....